Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms, drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Most patients relapse when BRAF or MEK inhibitors stop; intermittent dosing and ctDNA-guided discontinuation are being tested.
Nothing recorded yet.
Nothing recorded yet.
Background: Circulating tumour DNA (ctDNA). Also on OnCo: Treatment journeys · Survivorship planner.
Neurodegenerative ECD and LCH do not reverse with targeted therapy; earlier treatment and neuroprotective trials are the response.
Histiocytic sarcoma remains aggressive; MAPK inhibitors and immunotherapy are being tried.
Rarity: the Histiocyte Society, the ECD Global Alliance registry and NCCN's 2021 guideline coordinate what evidence exists.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
FDA approval October 2022 for adults with ECD, RDD and LCH.
Vemurafenib (FDA approval 2017) or dabrafenib, often with a MEK inhibitor to reduce toxicity; long-term treatment at the lowest effective dose.
Diamond and colleagues, Nature Medicine 2019.
Observation for asymptomatic nodal disease; surgery for isolated masses; steroids, sirolimus, cladribine or MEK inhibitors for symptomatic or multifocal disease.
Erdheim-Chester disease with BRAF V600 mutation